eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2021
vol. 18
 
Share:
Share:
Original paper

Iterative surgical resections in non-small cell lung cancer

Ahmet Ucvet
1
,
Serkan Yazgan
1
,
Ozgur Samancilar
2
,
Soner Gursoy
3
,
Ahmet Emin Erbaycu
4
,
Berna Komurcuoglu
5

  1. Department of Thoracic Surgery, Health Sciences University, Dr Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
  2. Department of Thoracic Surgery, Medicana International Izmir Hospital, Izmir, Turkey
  3. Department of Thoracic Surgery, Izmir Bakircay University, Izmir, Turkey
  4. Department of Pulmonology, Izmir Bakircay University, Izmir, Turkey
  5. Department of Pulmonology, Health Sciences University, Dr Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
Kardiochirurgia i Torakochirurgia Polska 2021; 18 (4): 221-226
Online publish date: 2022/01/09
Article file
- Iterative surgical.pdf  [0.14 MB]
Get citation
 
PlumX metrics:
 

Introduction

In patients undergoing curative resection for lung cancer, besides the significant risk of local recurrence, the risk of developing new lung cancer is also higher compared to the general population [15]. Regular and close follow-up after curative resection is therefore of great importance. When such new lesions are detected, a good prognosis can be achieved through a second surgical resection in early-stage patients showing no distant metastases and having sufficient cardiopulmonary reserve [57].

Aim

In this study, we examined the factors affecting the second surgical procedures performed due to lung malignancy, mortality, and survival rates in patients who underwent radical anatomical lung resection for non-small cell lung cancer (NSCLC), and tried to find some specific clues about the type and extent of the second surgery and patient selection.

Material and methods

We retrospectively analyzed data from a single institution, to identify patients who underwent surgical resection for lung cancer between January 1, 2010, and March 31, 2020. Inclusion criteria were as follows: 1) two separate curative-intent pulmonary resections for recurrent or second primary lung cancer; 2) lesion pathologically confirmed as primary NSCLC. Exclusion criteria were as follows: 1) carcinoid tumors; 2) those who underwent surgery due to pulmonary metastasis of an extrapulmonary malignancy; 3) those with extrathoracic metastasis; 4) those who underwent wedge resection in the first operation.

Operative mortality was defined as deaths before discharge from the hospital or within the first 30 days after the operation. Lesions that were not detected during the first operation and developed in the same or opposite lung within 24 months showing the same histology were defined as locally recurrent tumors. Concurrent tumors, regardless of histology, in the opposite lung without mediastinal nodal involvement, as well as those of different histology (synchronous) occurring within the first 24 months, or those of the same/different histology (metachronous) occurring after 24 months, were defined as the second primary tumor.

In the first postoperative period, patients were followed up by a thoracic surgeon 2 to 3 weeks after resection. Patients underwent radiological follow-up for at least 5 years; every 3 months for the first 2 years, every 6 months for the next 2 years, and then annually. 18 F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) was performed on those with suspicious lesions. Fiberoptic bronchoscopy and/or trans-thoracic fine-needle aspiration biopsy was performed when necessary. A second resection was performed in patients who showed no extrathoracic spread and had sufficient cardiopulmonary reserve if the lesion was only localized to the lung.

All medical records of the patients, operation notes of both procedures, pathology results, and postoperative follow-up records were examined. Survival was calculated by revising the date of death after the second surgery and by updating the records for the survivors on May 1, 2020, from the National Population Registration System, and all deaths were taken into account.

To analyze the condition in young and elderly patients, the patients included in the study were separated into two groups: those under 60 years of age and those aged 60 and over. Forced expiratory volume in 1 second (FEV1%) was classified as below 70%, and 70% and above. In the analysis of patients with comorbidities, chronic lung disease, heart disease, diabetes mellitus, and essential hypertension were taken into consideration. The preferred method of surgery was classified as video-assisted thoracic surgery (VATS) and thoracotomy.

The study was approved by the institutional review board (IRB date/no: 22.07.2020/49109414-604.02-7012).

Statistical analysis

The estimated survival rates were calculated using the Kaplan-Meier method. All deaths excluding operative mortality were taken into account. Variables affecting survival were compared using the log-rank test and Cox regression analysis. Among the groups, univariate analysis was performed using Fisher’s exact test or the Pearson χ2 test, and multivariate analysis was performed using binary logistic regression (forward stepwise). P < 0.05 was deemed significant. Variables with a p ≤ 0.25 in the univariate analysis were included in the multivariate analysis.

Results

Seventy-seven patients were included in the study and the mean age was 63 ±7.4 (46–83) years. In the first operation, lobectomy or bilobectomy was performed on most of the patients, while three patients underwent segmentectomy and one patient underwent pneumonectomy (Table I).

Table I

Patients’ data of the first operation

VariablesN%
Neoadjuvant treatmentNo6685.7
Yes1114.3
Surgical methodVATS1215.6
Thoracotomy6584.4
OperationSegmentectomy33.9
Lobectomy6685.7
Bilobectomy79.1
Pneumonectomy11.3
HistologySquamous4254.5
Non-squamous3545.5
Lymph node metastasisNo6381.8
Yes1418.2
Adjuvant treatmentNo5774
Yes2026

The mean time between the two operations was 36.7 (1–201) months. Squamous cell carcinoma was the most common among the histopathological types detected in both the first and the second operations (54.5% and 48.1%). VATS was performed in 12 (15.6%) patients for the first operation and 18 (23.4%) patients for the second operation. In the second operation of the patients who underwent VATS in the first operation, VATS was performed in 5 (41.7%) and thoracotomy in 7 (58.3%). In the second operation of the patients who underwent thoracotomy in the first operation, VATS was performed in 13 (20%) and thoracotomy in 52 (80%). Eight lobectomies, 2 segmentectomies, and 8 wedge resections were elected for VATS in the second surgery. Twenty-one completion pneumonectomies, 18 lobectomies, 2 segmentectomies, and 18 wedge resections were performed in patients who underwent thoracotomy in the second surgery. The patient characteristics of the second operations are shown in Table II. After the second operation, operative mortality occurred in 8 (10.4%) patients. Mortality was more common in patients who were old, had comorbidities, had a low FEV1 (%) value, underwent thoracotomy, underwent lobectomy or more extensive resection, and those on whom second surgery was performed in less than 36 months (Table III). However, this difference was statistically significantly higher in patients who underwent the only thoracotomy in both operations than in those who had VATS in at least one operation (p = 0.004) (Table IV).

Table II

Patient characteristics of the second operation

VariablesN%
Total77100
Sex:
 Male6888.3
 Female911.7
Age group:
 < 60 years3039
 ≥ 60 years4761
Comorbidity:
 No5166.2
 Yes2633.8
FEV1 (%):
 < 703748.1
 ≥ 704051.9
Surgical method:
 VATS1823.4
 Thoracotomy5976.6
 Wedge2633.8
 Segmentectomy45.2
Operation:
 Lobectomy2431.2
 Bilobectomy22.6
 Pneumonectomy2127.3
 Squamous cell3748.1
Histology:
 Adenocarcinoma3444.2
 Large cell67.8
Size:
 ≤ 3 cm6179.2
 > 3 cm1620.8
Resection:
 Complete7597.4
 Incomplete22.6
Lymph node metastasis:
 No6787
 Yes1013
Stage:
 I6280
 II–III1520
Adjuvant treatment:
 No4659.7
 Yes3140.3
Histology:
 Same6685.7
 Different1114.3
Side:
 Ipsilateral2735.1
 Contralateral5064.9
Indication:
 Recurrent2329.9
 Second primary5470.1
Period until the second operation:
 36 months and less4659.7
 Over 36 months3140.3
Table III

Characteristics of patients with postoperative mortality

PatientsAge ≥ 60FEV1 < 70%ComorbidityThoracotomy in both operationsLobectomy or more extensive resectionInterval more than 36 monthsCauses of death
1+++++Peroperative bleeding
2+++++ARDS
3++++++ARDS
4++++ARDS
5++++Cardiac event
6+++++Cardiac event
7++++Cardiac event
8++++Pneumonia

[i] ARDS – acute respiratory distress syndrome.

Table IV

Analysis of variables affecting mortality based on the second operations

VariablesMortalityP-value
N%UnivariateMultivariate
Total810.4
SexMale710.31
Female111.1
AgeYoung26.70.47
Old612.8
ComorbidityNo47.80.43
Yes415.4
FEV1 (%)< 70616.20.140.1
≥ 7025
Surgical methodVATS000.190.1
Thoracotomy813.6
Extent of the surgeryLimited resection13.30.140.1
Lobectomy or more extensive714.9
Period until the second operation36 months and less36.50.250.18
Over 36 months516.1
IndicationRecurrent14.30.42
Second primary713
Surgical method on the contralateral sideAt least one VATS000.0480.038
Thoracotomy815.8
SideIpsilateral311.11
Contralateral510

During a mean follow-up of 33.4 months (1.5–123 months), 27 patients died, excluding operative mortality, while 42 patients were still alive. The 5-year overall survival rate was 46.5%, and the mean and median survival rates were 68.5 months and 57.8 months, respectively (Figure 1).

Figure 1

Overall survival curve after the second surgery, excluding postoperative mortality

/f/fulltexts/KiTP/46004/KITP-18-46004-g001_min.jpg

Five-year survival in patients operated on for recurrent and second primary tumor was 32.8% and 51.1%, respectively (p = 0.81). When we examined the subgroups of the second primary tumor, we found that 5-year survival was 65.1% in metachronous tumors, while 4-year survival was 38% in synchronous tumors, and no patients in this group had lived for 5 years (p = 0.078). The 5-year survival rate was 21.8% for patients who underwent two operations within less than 36 months, while it was 72.2% for those who had the second operation after more than 36 months (p = 0.028) (Figure 2). Additionally, in univariate analysis, the survival rate was found to be significantly lower in elderly patients (p = 0.004). In the Cox regression analysis, only age group was identified as a statistically significant variable for survival (p = 0.019; odd ratio (OR) = 3.1; confidence interval (CI) = 1.2–8.0) (Table V).

Table V

Variables affecting survival

VariablesN5-year survivalP-value (log-rank)P-value (Cox reg)
Total6946.5
SexMale6146.60.3
Female842.9
Age< 60 years2868.80.0040.019
> 60 years4127.5
ComorbidityNo4748.30.89
Yes2224.9
FEV1 (%)Below 703169.10.20.27
70 and above3834.2
Extent of the surgeryLimited resection2956.70.240.6
Lobectomy or more extensive4036.3
ResectionComplete67470.58
Incomplete250
Size3 cm and smaller54450.51
Larger than 3 cm1548
Nodal metastasisNo6049.30.230.78
Yes935.6
StageI5549.50.18
II–III1437.6
HistologySame5946.40.97
Different1041.7
SideIpsilateral2439.90.95
Contralateral4548.3
IndicationRecurrent2232.80.81
Second primary4751.1
AdjuvantNo3850.30.220.18
Yes3144.7
Period of time until the second operation36 months and less4321.80.0280.33
Over 36 months2672.2
Surgical method on the contralateral sideAt least one VATS2537.10.180.9
Thoracotomy4452.2
Figure 2

Survival curves for intervals shorter and longer than 36 months

/f/fulltexts/KiTP/46004/KITP-18-46004-g002_min.jpg

Discussion

In parallel with the developments in techniques for lung cancer diagnosis and treatment, the number of patients receiving early diagnosis and treatment is gradually increasing. The number of patients living after curative treatment and their lifespan are also increasing [8]. It is known that these patients have a significant risk of local recurrence and an increased risk of developing new lung cancer [15]. Through advanced examination techniques and postoperative close follow-up, potentially treatable, new, and recurrent cancers can be detected at an early stage more frequently [2]. Throughout the study period of more than 10 years, second lung cancer surgery was performed in 4% of 1925 patients who had previously undergone an operation for lung cancer in our clinic. In different series, this rate is reported between 3.1% and 4.1% [3, 5, 6, 9].

Due to the patient’s age, loss of respiratory function caused by the first surgery, side effects related to treatments such as chemotherapy/radiotherapy, if received, and the presence of more additional diseases, the mortality rates of surgical procedures to be performed increase compared to those who have surgery for the first time. In the literature, the postoperative mortality rate is reported to be in the range 0–29%, depending on the diagnosis and extent of resection [1, 3, 6, 1013]. In our study, this rate was calculated as 10.4%. Similar to the literature, the postoperative mortality rate was higher in our patients who were old, had comorbidities, underwent thoracotomy, had a longer interval between operations, and underwent lobectomy or more extensive resection [1416]. When we consider the extent of the resection in the second operation of eight patients with postoperative mortality, we see that sublobar resection was performed in only one patient. Lobectomy or pneumonectomy was performed in the other seven patients. However, only those who underwent thoracotomy in both operations had significantly higher postoperative mortality. This can be attributed to the lower postoperative morbidity and mortality in patients undergoing resection through VATS, as well as the fact that VATS is preferred by thoracic surgeons for less risky procedures. Similar to our study, studies comparing VATS with thoracotomy have reported in recent years that postoperative mortality is lower in VATS cases [14, 17].

In many studies in the literature, a second resection has been recommended for selected patients with NSCLC detected after curative lung resection [57]. In different series, 5-year survival rates following second resections performed due to various indications are reported to be between 30% and 69% [5, 10, 12, 18]. In our series, the overall 5-year survival rate was 46.5% and age was the only significant variable affecting survival. Okubo et al. [7] suggested that node metastasis, age, and disease-free period affect survival, while Lee et al. [5] reported that the only variable affecting survival is stage. Both studies emphasized that surgery can yield long-term survival in patients with adequate cardiopulmonary reserve. Some studies have argued that it does not affect the prognosis whether the histology is the same or different and whether the lesion is ipsilateral or contralateral [5, 6]. It was also observed in our series that, besides the histological type of the two tumors, whether the second tumor was located on the ipsilateral or contralateral side, whether the FEV1 value was below or above 70%, tumor size, or nodal metastasis does not have any impact on 5-year survival.

Although recurrence is primarily considered for newly developing lung cancer in a patient receiving curative treatment due to primary lung cancer, this may be a synchronous or metachronous tumor. In the literature, 5-year survival was reported to be in the range of 15–43% in recurrent tumors [1, 7, 10, 19], while this rate was 19% to 87% in synchronous and metachronous tumors, and there was no significant difference between the groups in these studies [1, 6, 9, 10, 13, 18, 19]. In our study, this rate was 32.8% in recurrent tumors and 51.1% in second primary NSCLC (p = 0.81). In a recently published meta-analysis, 10 articles discussing synchronous and metachronous tumors were reviewed. According to this analysis, excluding a study specific to tumors with adenocarcinoma histology, the median survival for synchronous tumors was reported to be between 32 and 55 months and 5-year survival was between 19% and 40% [13]. In our series, the median survival for synchronous tumors was 33.9 months, and 4-year survival was 38%. In the same meta-analysis, the 5-year survival of metachronous tumors was reported to be in the range of 32% to 66%, and this rate was similarly 65.1% in our series.

While Okubo et al. [7] reported that the disease-free period between two operations is a poor prognostic factor for decreased survival, different studies argued that the interval between the operations has no significant impact on survival [5, 6, 12]. In our study, the 5-year survival rates calculated for the second surgery performed before or after 36 months were 21.8% and 72.2%, respectively. While this difference was significant in univariate analysis (p = 0.028), it did not emerge as a significant prognostic factor in Cox regression analysis (p = 0.33).

Another disputable issue is the extent of the second surgical resection to be performed. Depending on the location and size of the lesion, completion lobectomy or completion pneumonectomy may be required in the second operation; however, sublobar resections may also be preferred in early-stage patients. In our study, limited resection was preferred in eligible patients in the second operation as much as possible. These patients had a better, although not statistically significant, survival rate compared to those with more extensive resections. The 5-year survival rate was 56.7% for sublobar resection, and 36.3% for lobectomy or more extensive resection (p = 0.24). It has also been reported in the literature that more limited resections can be performed with similar survival rates in eligible patients [5, 9, 18].

Our study has some limitations. Firstly, this is a retrospective study. Secondly, this is a single-center study. If we had included more health centers and compared other results, the results would be more objective. Thirdly, the small number of our patients in some subgroups made it difficult for us to analyze some data, although it is not different from the series in the literature.

Conclusions

In our experience, surgical resection for iterative NSCLC significantly prolongs survival. Younger patients with more limited resections, performing VATS in at least one of the two operations, and an interval of more than 36 months between the two operations have a better prognosis.

Disclosure

The authors report no conflict of interest.

References

1 

Voltolini L, Paladini P, Luzzi L, Ghiribelli C, Di Bisceglie M, Gotti G , authors. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg. 2000. 18:p. 529–534

2 

Van Schil PE , author. Follow-up after lung cancer resection: is intensified also justified? Eur Respir J. 2013. 42:p. 1178–1179

3 

Egermann U, Jaeggi K, Habicht JM, Perruchoud AP, Dalquen P, Soler M , authors. Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? Eur Respir J. 2002. 19:p. 464–468

4 

Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM , authors. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer. 2009. 115:p. 1059–1069

5 

Lee BE, Port JL, Stiles BM, Saunders JA, Paul S, Lee PC, Altorki N , authors. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg. 2009. 88:p. 1100–1105

6 

Battafarano RJ, Force SD, Meyers BF, Bell J, Guthrie TJ, Cooper JD, Patterson GA , authors. Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg. 2004. 127:p. 836–842

7 

Okubo K, Bando T, Miyahara R, Sakai H, Shoji T, Sonobe M, Fujinaga T, Sato K, Wada H, Tanaka T , authors. Resection of pulmonary metastasis of non-small cell lung cancer. J Thorac Oncol. 2009. 4:p. 203–207

8 

Ucvet A, Gursoy S, Yazgan S , authors. Changes in the surgical treatment strategies for nonsmall cell lung cancer in the past 20 years: a single-center experience. Turk Thorac J. 2020. 21:p. 8–13

9 

Togashi K, Hosaka Y, Okada A, Sato S , authors. Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection. Kyobu Geka. 2010. 63:p. 963–968

10 

Guggino G, Doddoli C, Barlesi F, Acri P, Chetaille B, Thomas P, Giudicelli R, Fuentes P , authors. Completion pneumonectomy in cancer patients: experience with 55 cases. Eur J Cardiothorac Surg. 2004. 25:p. 449–455

11 

Cardilloa G, Galettab D, van Schil P, Zuind A, Filossoe P, Cerfolio RJ, Forcione AR, Carleo F , authors. Completion pneumonectomy: a multicentre international study on 165 patients. Eur J Cardiothorac Surg. 2012. 42:p. 405–409

12 

Kim HS, Hoseok I, Choi YS, Kim K, Shim YM, Kim J , authors. Surgical resection of recurrent lung cancer in patients following curative resection. J Korean Med Sci. 2006. 21:p. 224–228

13 

Chen TF, Xie CY, Rao BY, Shan SC, Zhang X, Zeng B, Lei YY, Luo HH , authors. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg. 2019. 19:p. 185

14 

Hamaji M, Cassivi SD, Shen KR, Allen MS, Nichols FC, Deschamps C, Wigle DA , authors. Prior thoracoscopic surgery may improve reoperative pulmonary resection. Asian Cardiovasc Thorac Ann. 2014. 22:p. 700–705

15 

Harpole DH, DeCamp MM, Daley J, Hur K, Oprian CA, Henderson WG, Khuri SF , authors. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg. 1999. 117:p. 969–979

16 

Myrdal G, Gustafsson G, Lambe M, Hörte LG, Ståhle E , authors. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg. 2001. 20:p. 694–699

17 

Al-Ameri M, Bergman P, Franco-Cereceda A, Sartipy U , authors. Video-assisted thoracoscopic versus open thoracotomy lobectomy: a Swedish nationwide cohort study. J Thorac Dis. 2018. 10:p. 3499–3506

18 

Terzi A, Lonardoni A, Scanagatta P, Pergher S, Bonadiman C, Calabro F , authors. Lung resection for bronchogenic carcinoma after pneumonectomy: a safe and worthwhile procedure. Eur J Cardiothorac Surg. 2004. 25:p. 456–459

19 

Kawashima O, Ibe T, Kakegawa S, Nakano T, Shimizu K , authors. Surgical treatment and outcome for postoperative recurrent or second primary lung cancer. Kyobu Geka. 2010. 63:p. 935–939

Copyright: © 2022 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.